The complexity of platelet metabolism and its contribution to atherothrombosis

Acta Cardiologica

Volumn 64, Issue 2, 2009, Pages 157-165

  Puddu, Paolo ^a   Muscari, Antonio ^a   Puddu, Giovanni M ^a   Cravero, Eleonora ^a   Giannoni, Claudia ^a   Zoli, Marco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Atherosclerosis; Inflammation; Pathophysiology; Platelets; Thrombosis

Indexed keywords

CD31 ANTIGEN; COLLAGEN; FIBRINOGEN RECEPTOR; FIBRONECTIN; GLYCOPROTEIN IB ALPHA; GLYCOPROTEIN VI; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 4; PURINERGIC P2X RECEPTOR; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; SEMAPHORIN; SEMAPHORIN 4D; THROMBOXANE A2 RECEPTOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE METABOLISM; THROMBOCYTE STRUCTURE; THROMBOSIS;

ANIMALS; ATHEROSCLEROSIS; BLOOD PLATELETS; HUMANS; PLATELET AGGREGATION; PROGNOSIS; RISK FACTORS; THROMBOSIS;

EID: 65349114763     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.64.2.2035338     Document Type: Review

References (107)

1. Freedman JE. Molecular regulation of platelet-dependent thrombosis. Circulation 2005; 112: 2725-34.
2. Andreotti F, Becker RC. Atherothrombotic disorders: new insights from hematology. Circulation 2005; 111: 1855-63.
3. Gawaz M. Platelets in the onset of atherosclerosis. Blood Cells Mol Dis 2006; 36: 206-10.
4. Willoughby S, Holmes A, Loscalzo J. Platelets and cardio-vascular disease. Eur J Cardiovasc Nurs 2002; 1 273-88.
5. Baruch D. Platelet-vessel wall interactions [in French]. Therapie 2006; 61: 371-8.
6. Andrews RK, Gardiner EE, Shen Y, Berndt MC. Platelet interactions in thrombosis. IUBMB Life 2004; 56: 13-8.
7. Denis CV, Wagner DD. Platelet adhesion receptors and their ligands in mouse models of thrombosis. Arterioscler Thromb Vasc Biol 2007; 27: 728-39.
8. Jackson SP. The growing complexity of platelet aggregation. Blood 2007; 109: 5087-95.
9. Huo Y, Ley KF. Role of platelets in the development of atherosclerosis. Trends Cardiovasc Med 2004; 14: 18-22.
10. Puddu P, Cravero E, Puddu GM, Muscari A. Genes and atherosclerosis: at the origin of the predisposition. Int J Clin Pract 2005; 59: 462-72.
11. Puddu GM, Cravero E, Arnone G, Muscari A, Puddu P. Molecular aspects of atherogenesis: new insights and unsolved questions. J Biomed Sci 2005; 12: 839-53.
12. Puddu P, Puddu GM, Galletti L, Cravero E, Muscari A. Mitochondrial dysfunction as an initiating event in atherogenesis: a plausible hypothesis. Cardiology 2005; 103: 137-41.
13. Kaushansky K. Thrombopoietin and hematopoietic stem cell development. Ann N Y Acad Sci 1999; 872: 314-9.
14. Battinelli E, Willoughby SR, Foxall T, Valeri CR, Loscalzo J. Induction of platelet formation from megakaryocytoid cells by nitric oxide. Proc Natl Acad Sci U S A 2001; 98: 14458-63.
15. Troxler M, Dickinson K, Homer-Vanniasinkam S. Platelet function and antiplatelet therapy. Br J Surg 2007; 94: 674-82.
16. Papanas N, Symeonidis G, Maltezos E, Mavridis G, Karavageli E, Vosnakidis T, Lakasas G. Mean platelet volume in patients with type 2 diabetes mellitus. Platelets 2004; 15: 475-8.
17. Coban E, Ozdogan M, Yazicioglu G, Akcit F. The mean platelet volume in patients with obesity. Int J Clin Pract 2005; 59: 981-2.
18. Endler G, Klimesch A, Sunder-Plassmann H, Schillinger M, Exner M, Mannhalter C, Jordanova N, Christ G, Thalhammer R, Huber K, Sunder-Plassmann R. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 2002; 117: 399-404.
19. Bath P, Algert C, Chapman N, Neal B; PROGRESS Collaborative Group. Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke 2004; 35: 622-6.
20. Riondino S, Gazzaniga PP, Pulcinelli FM. Convulxin induces platelet shape change through myosin light chain kinase and Rho kinase. Eur J Biochem 2002; 269: 5878-84.
21. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8: 1227-34.
22. Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res 2007; 100: 1673-85.
23. Ruggeri ZM. The role of von Willebrand factor in thrombus formation. Thromb Res 2007; 120 Suppl 1: S5-9.
24. Aoki R, Ikarugi H, Naemura A, Ijiri Y, Yamashita T, Yamamoto J. Endothelial dysfunction precedes atherosclerotic lesions and platelet activation in high fat diet-induced prothrombotic state. Thromb Res 2006; 117: 529-35.
25. Schafer A, Alp NJ, Cai S, Lygate CA, Neubauer S, Eigenthaler M, Bauersachs J, Channon KM. Reduced vascular NO bioavailability in diabetes increases platelet activation in vivo. Arterioscler Thromb Vasc Biol 2004; 24: 1720-6.
26. Johnson RC, Mayadas TN, Frenette PS, Mebius RE, Subramaniam M, Lacasce A, Hynes RO, Wagner DD. Blood cell dynamics in P-selectin-deficient mice. Blood 1995; 86: 1106-14.
27. Frenette PS, Johnson RC, Hynes RO, Wagner DD. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci U S A 1995; 92: 7450-4.
28. Frenette PS, Moyna C, Hartwell DW, Lowe JB, Hynes RO, Wagner DD. Platelet-endothelial interactions in inflamed mesenteric venules. Blood 1998; 91: 1318-24.
29. Massberg S, Gruner S, Konrad I, Garcia Arguinzonis MI, Eigenthaler M, Hemler K, Kersting J, Schulz C, Muller I, Besta F, Nieswandt B, Heinzmann U, Waiter U, Gawaz M. Enhanced in vivo platelet adhesion in vasodilator-stimulated phosphoprotein (VASP)-deficient mice. Blood 2004; 103: 136-42.
30. Massberg S, Enders G, Leiderer R, Eisenmenger S, Vestweber D, Krombach F, Messmer K. Platelet-endothelial cell interactions during ischemia/ reperfusion: the role of P-selectin. Blood 1998; 92: 507-15.
31. Massberg S, Sausbier M, Klatt P, Bauer M, Pfeifer A, Siess W, Fassler R, Ruth P, Krombach F, Hofmann F. Increased adhesion and aggregation of platelets lacking cyclic guanosine 3′,5′-monophosphate kinase I. J Exp Med 1999; 189: 1255-64.
32. Massberg S, Enders G, Matos FC, Tomic LI, Leiderer R, Eisenmenger S, Messmer K, Krombach F. Fibrinogen deposition at the postischemic vessel wall promotes platelet adhesion during ischemia-reperfusion in vivo. Blood 1999; 94: 3829-38.
33. Farndale RW, Sixma JJ, Barnes MJ, de Groot PG. The role of collagen in thrombosis and hemostasis. J Thromb Haemost 2004; 2: 561-73.
34. Hindriks G, Ijsseldijk MJ, Sonnenberg A, Sixma JJ, de Groot PG. Platelet adhesion to laminin: role of Ca2 + and Mg2 + ions, shear rate, and platelet membrane glycoproteins. Blood 1992; 79: 928-35.
35. Godyna S, Diaz-Ricart M, Argraves WS. Fibulin-1 mediates platelet adhesion via a bridge of fibrinogen. Blood 1996; 88: 2569-77.
36. Jurk K, Clemetson KJ, de Groot PG, Brodde MF, Steiner M, Savion N, Varon D, Sixma JJ, Van Aken H, Kehrel BE. Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein Ib (GPIb): an alternative/backup mechanism to von Willebrand factor. FASEB J 2003; 17: 1490-2.
37. Romo GM, Dong JF, Schade AJ, Gardiner EE, Kansas GS, Li CQ, McIntire LV, Berndt MC, Lopez JA. The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J Exp Med 1999; 190: 803-14.
38. Dong JF. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost 2005; 3: 1710-6.
39. Padilla A, Moake JL, Bernardo A, Ball C, Wang Y, Arya M, Nolasco L, Turner N, Berndt MC, Anvari B, Lopez JA, Dong JF. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface. Blood 2004; 103: 2150-6.
40. Simon DI, Chen Z, Xu H, Li CQ, Dong J, McIntire LV, Ballantyne CM, Zhang L, Furman MI, Berndt MC, Lopez JA. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med 2000; 192: 193-204.
41. Baglia FA, Badellino KO, Li CQ, Lopez JA, Walsh PN. Factor XI binding to the platelet glycoprotein Ib-IX-V complex promotes factor XI activation by thrombin. J Biol Chem 2002; 277: 1662-8.
42. Yun TH, Baglia FA, Myles T, Navaneetham D, Lopez JA, Walsh PN, Leung LL. Thrombin activation of factor XI on activated platelets requires the interaction of factor XI and platelet glycoprotein Ib alpha with thrombin anion-binding exosites I and II, respectively. J Biol Chem 2003; 278: 48112-9.
43. Bradford HN, Pixley RA, Colman RW. Human factor XII binding to the glycoprotein Ib-IX-V complex inhibits thrombin-induced platelet aggregation. J Biol Chem 2000; 275: 22756-63.
44. Joseph K, Nakazawa Y, Bahou WF, Ghebrehiwet B, Kaplan AP. Platelet glycoprotein Ib: a zinc-dependent binding protein for the heavy chain of high-molecular-weight kininogen. Mol Med 1999; 5: 555-63.
45. Dumas JJ, Kumar R, Seehra J, Somers WS, Mosyak L. Crystal structure of the GpIbalpha-thrombin complex essential for platelet aggregation. Science 2003; 301: 222-6.
46. Celikel R, McClintock RA, Roberts JR, Mendolicchio GL, Ware J, Varughese KI, Ruggeri ZM. Modulation of alphathrombin function by distinct interactions with platelet glycoprotein Ibalpha. Science 2003; 301: 218-21.
47. Adam F, Bouton MC, Huisse MG, Jandrot-Perrus M. Thrombin interaction with platelet membrane glycoprotein Ib alpha. Trends Mol Med 2003; 9: 461-4.
48. Vanhoorelbeke K, Ulrichts H, Romijn RA, Huizinga EG, Deckmyn H. The GPIbalpha-thrombin interaction: far from crystal clear. Trends Mol Med 2004; 10: 33-9.
49. Steinhubl SR, Moliterno DJ. The role of the platelet in the pathogenesis of atherothrombosis. Am J Cardiovasc Drugs 2005; 5: 399-408.
50. Andrews RK, Karunakaran D, Gardiner EE, Berndt MC. Platelet receptor proteolysis: a mechanism for downregulating platelet reactivity. Arterioscler Thromb Vasc Biol 2007; 27: 1511-20.
51. Inoue O, Suzuki-Inoue K, McCarty OJ, Moroi M, Ruggeri ZM, Kunicki TJ, Ozaki Y, Watson SP. Laminin stimulates spreading of platelets through integrin alpha6beta1-dependent activation of GPVI. Blood 2006; 107: 1405-12.
52. Polgar J, Clemetson JM, Kehrel BE, Wiedemann M, Magnenat EM, Wells TN, Clemetson KJ. Platelet activation and signal transduction by convulxin, a C-type lectin from Crotalus durissus terrificus (tropical rattlesnake) venom via the p62/GPVI collagen receptor. J Biol Chem 1997; 272: 13576-83.
53. Andrews RK, Gardiner EE, Asazuma N, Berlanga O, Tulasne D, Nieswandt B, Smith AI, Berndt MC, Watson SP. A novel viper venom metalloproteinase, alborhagin, is an agonist at the platelet collagen receptor GPVI. J Biol Chem 2001; 276: 28092-7.
54. Wee JL, Jackson DE. The Ig-ITIM superfamily member PECAM-1 regulates the "outside-in" signaling properties of integrin alpha(IIb)beta3 in platelets. Blood 2005; 106: 3816-23.
55. Rathore V, Stapleton MA, Hillery CA, Montgomery RR, Nichols TC, Merricks EP, Newman DK, Newman PJ. PECAM-1 negatively regulates GPIb/V/IX signaling in murine platelets, Blood 2003; 102: 3658-64.
56. Falati S, Patti S, Gross PL, Stapleton M, Merrill-Skoloff G, Barrett NE, Pixton KL, Weiler H, Cooley B, Newman DK, Newman PJ, Furie BC, Furie B, Gibbins JM. Platelet PECAM-1 inhibits thrombus formation in vivo. Blood 2006; 107: 535-41.
57. Zhu L, Bergmeier W, Wu J, Jiang H, Stalker TJ, Cieslak M, Fan R, Boumsell L, Kumanogoh A, Kikutani H, Tamagnone L, Wagner DD, Milla ME, Brass LF. Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury. Proc Natl Acad Sci U S A 2007; 104: 1621-6.
58. Voss B, McLaughlin JN, Holinstat M, Zent R, Hamm HE. PAR1, but not PAR4, activates human platelets through a Gi/o/phosphoinositide-3 kinase signaling axis. Mol Pharmacol 2007; 71: 1399-406.
59. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 2004; 61: 498-511.
60. Santos-Martinez MJ, Medina C, Jurasz P, Radomski MW. Role of metalloproteinases in platelet function. Thromb Res 2008; 121: 535-42.
61. Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW. Release of gelatinase A during platelet activation mediates aggregation. Nature 1997; 386: 616-9.
62. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis, J Clin Invest 2005; 115: 3378-84.
63. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2003; 23: 2131-7.
64. Iannacone IM, Sitia G, Isogawa M, Marchese P, Castro MG, Lowenstein PR, Chisari FV, Ruggeri ZM, Guidotti LG. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med 2005; 11: 1167-9.
65. Loscalzo J. Oxidant stress: a key determinant of atherothrombosis. Biochem Soc Trans 2003; 31: 1059-61.
66. Minuz P, Patrignani P, Gaino S, Seta F, Capone ML, Tacconelli S, Degan M, Faccini G, Fornasiero A, Talamini G, Tommasoli R, Arosio E, Santonastaso CL, Lechi A, Patrono C. Determinants of platelet activation in human essential hypertension. Hypertension 2004; 43: 64-70.
67. Krötz F, Sohn HY, Gloe T, Zahler S, Riexinger T, Schiele TM, Becker BF, Theisen K, Klauss V, Pohl U. NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood 2002; 100: 917-24.
68. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ 2nd. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990; 87: 9383-7.
69. Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 2005; 25: 279-86.
70. Praticò D, Smyth EM, Violi F, FitzGerald GA. Local amplification of platelet function by 8-Epi prostaglandin F2alpha is not mediated by thromboxane receptor isoforms. J Biol Chem 1996; 271: 14916-24.
71. Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res 2005; 96: 612-6.
72. Schnackenberg CG, Wilcox CS. Two-week administration of tempol attenuates both hypertension and renal excretion of 8-Iso prostaglandin f2alpha. Hypertension 1999; 33: 424-8.
73. Kerr S, Brosnan MJ, McIntyre M, Reid JL, Dominiczak AF, Hamilton CA. Superoxide anion production is increased in a model of genetic hypertension: role of the endothelium. Hypertension 1999; 33: 1353-8.
74. Zalba G, Beaumont FJ, San José G, Fortuño A, Fortuño MA, Etayo JC, Díez J. Vascular NADH/NADPH oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. Hypertension 2000; 35: 1055-61.
75. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998; 97: 2222-9.
76. Solzbach U, Hornig B, Jeserich M, Just H. Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation 1997; 96: 1513-9.
77. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, Channon KM. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res 2000; 86: E85-90.
78. Davì G, Di Minno G, Coppola A, Andria G, Cerbone AM, Madonna P, Tufano A, Falco A, Marchesani P, Ciabattoni G, Patrono C. Oxidative stress and platelet activation in homozygous homocystinuria. Circulation 2001; 104: 1124-8.
79. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996; 98: 5-7.
80. Ferroni P, Basili S, Falco A, Davì G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004; 2: 1282-91.
81. Weyrich A, Cipollone F, Mezzetti A, Zimmerman G. Platelets in atherothrombosis: new and evolving roles. Curr Pharm Des 2007; 13: 1685-91.
82. May AE, Seizer P, Gawaz M. Platelets: inflammatory fire-bugs of vascular walls. Arterioscler Thromb Vasc Biol 2008; 28: s5-10.
83. Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-41.
84. May AE, Langer H, Seizer P, Bigalke B, Lindemann S, Gawaz M. Platelet-leukocyte interactions in inflammation and atherothrombosis. Semin Thromb Hemost 2007; 33: 123-7.
85. Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-94.
86. Borrelli V, di Marzo L, Sapienza P, Colasanti M, Moroni E, Cavallaro A. Role of platelet-derived growth factor and transforming growth factor betal the in the regulation of metalloproteinase expressions. Surgery 2006; 140: 454-63.
87. Schmidt R, Bültmann A, Fischel S, Gillitzer A, Cullen P, Walch A, Jost P, Ungerer M, Tolley ND, Lindemann S, Gawaz M, Schömig A, May AE. Extracellular matrix metalloproteinase inducer (CD147) is a novel receptor on platelets, activates platelets, and augments nuclear factor kappaB-dependent inflammation in monocytes. Circ Res 2008; 102: 302-9.
88. Ernst RL, Ammar AD, Lin JJ, Travers H. The effect of antiplatelet therapy on the incidence of carotid plaque hemorrhage. Stroke 1986; 17: 540-1.
89. Massberg S, Brand K, Gruner S, Page S, Muller E, Muller I, Bergmeier W, Richter T, Lorenz M, Konrad I, Nieswandt B, Gawaz M. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002; 196: 887-96.
90. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991; 67: 1033-6.
91. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301-14.
92. McIntyre TM, Prescott SM, Weyrich AS, Zimmerman GA. Cell-cell interactions: leukocyte-endothelial interactions. Curr Opin Hematol 2003; 10: 150-8.
93. Kuijper PH, Gallardo Torres HI, van der Linden JA, Lammers JW, Sixma JJ, Koenderman L, Zwaginga JJ. Platelet-dependent primary hemostasis promotes selectin- and integrin-mediated neutrophil adhesion to damaged endothelium under flow conditions. Blood 1996; 87: 3271-81.
94. Arber N, Berliner S, Pras E, Arber L, Fishelson Z, Kahn Y, Bassat MB, Pinkhas J, Aron. Heterotypic leukocyte aggregation in the peripheral blood of patients with leukemia, inflammation and stress. Nouv Rev Fr Hematol 1991; 33: 251-5.
95. Schober A, Manka D, von Hundelshausen P, Hut Y, Hanrath P, Sarembock IJ, Ley K, Weber C. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 2002; 106: 1523-9.
96. Gaboury JP, Niu XF, Kubes P. Nitric oxide inhibits numerous features of mast cell-induced inflammation. Circulation 1996; 93: 318-26.
97. Niu XF, Smith CW, Kubes P. Intracellular oxidative stress induced by nitric oxide synthesis inhibition increases endothelial cell adhesion to neutrophils. Circ Res 1994; 74: 1133-40.
98. Schulz C, Schafer A, Stolla M, Kerstan S, Lorenz M, von Bruhl ML, Schiemann M, Bauersachs J, Gloe T, Busch DH, Gawaz M, Massberg S. Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets. Circulation 2007; 116: 764-73.
99. Tull SP, Anderson SI, Hughan SC, Watson SP, Nash GB, Rainger GE. Cellular pathology of atherosclerosis: smooth muscle cells promote adhesion of platelets to cocultured endothelial cells. Circ Res 2006; 98: 98-104.
100. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol 1995; 57: 791-804.
101. Rosenblum WI. Platelet adhesion and aggregation without endothelial denudation or exposure of basal lamina and/or collagen. J Vasc Res 1997; 34: 409-17.
102. Ware JA, Heistad DD. Seminars in medicine of the Beth Israel Hospital, Boston. Platelet-endothelium interactions. N Engl J Med 1993; 328: 628-35.
103. Methia N, Andre P, Denis CV, Economopoulos M, Wagner DD. Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood 2001; 98: 1424-8.
104. yon Hundelshausen P, Petersen F, Brandt E. Platelet-derived chemokines in vascular biology. Thromb Haemost 2007; 97: 704-13.
105. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007; 100: 27-40.
106. Afshar-Kharghan V, Thiagarajan P. Leukocyte adhesion and thrombosis. Curr Opin Hematol 2006; 13: 34-9.
107. Steinhubl SR. Platelets as mediators of inflammation. Hematol Oncol Clin North Am 2007; 21: 115-21.